Tirzepatide is a synthetic peptide engineered to mimic incretin hormones, specifically glucose-dependent insulinotropic polypeptide (GIP) while also activating the glucagon-like peptide-1 (GLP-1) receptor. These hormones play a central role in regulating glucose metabolism, insulin signaling, appetite, and energy balance.

Tirzepatide was designed as a dual incretin receptor agonist, meaning it can activate both GIP and GLP-1 pathways simultaneously. Its peptide sequence is primarily based on the natural GIP hormone, but it includes several structural modifications and a fatty-acid side chain attachment, which:

Enhances receptor activity at both GIP and GLP-1 receptors

Extends the peptide’s stability and biological activity through strong albumin binding

Allows for a significantly prolonged half-life (approximately 5 days in pharmacokinetic studies) compared with natural incretin hormones, which are normally broken down within minutes in the body

These modifications improve the peptide’s resistance to enzymatic degradation and extend its functional activity in metabolic signaling systems compared with native incretin hormones.

Tirzepatide is commonly supplied in lyophilized form for laboratory investigation, where it is studied for its effects on incretin receptor signaling, insulin secretion pathways, glucose regulation, and metabolic research models. Research-grade preparations are typically labeled for laboratory research use only and not approved for direct human or veterinary therapeutic use outside of regulated pharmaceutical products.